J Med Microbiol 2003, 52:337–344.PubMedCrossRef 34. Salloum M, van der Mee-Marquet N, Domelier AS, Arnault L, Quentin R: Molecular characterization and prophage DNA contents of Streptococcus agalactiae strains isolated from adult skin and osteoarticular infections. J Clin Microbiol 2010, 48:1261–1269.PubMedCrossRef 35. Agnew W, Barnes AC: Streptococcus iniae:

an aquatic pathogen of global veterinary significance Selisistat mw and a challenging candidate for reliable vaccination. Vet Microbiol 2007, 122:1–15.PubMedCrossRef 36. Haguenoer E, Baty G, Pourcel C, Lartigue MF, Domelier AS, Rosenau A, et al.: A multi locus variable number of tandem repeat analysis (MLVA) scheme for Streptococcus agalactiae genotyping. BMC Microbiol 2011, 11:171.PubMedCrossRef 37. Elliott JA, Facklam RR, Richter CB: Whole-cell protein patterns of nonhemolytic group B, type Ib, streptococci isolated from humans, mice, cattle, frogs, and fish. J Clin Microbiol 1990, 28:628–630.PubMed 38. Evans JJ, Pasnik DJ, Klesius PH, Al-Ablani S: First report of Streptococcus agalactiae and Lactococcus garvieae from a wild bottlenose dolphin

(Tursiops truncatus). J Wildl Dis 2006, 42:561–569.PubMed 39. Lartigue MF, Héry-Arnaud G, Haguenoer E, Domelier AS, Schmit PO, Mee-Marquet N, et DMXAA al.: Identification of Streptococcus agalactiae isolates from various

phylogenetic lineages by matrix-assisted laser desorption ionization-time of flight mass Florfenicol spectrometry. J Clin Microbiol 2009, 47:2284–2287.PubMedCrossRef 40. Baker JR: Further studies on grey seal (Halichoerus grypus) pup mortality on North Rona. Br Vet J 1988, 144:497–506.PubMedCrossRef 41. Baker JR, Crenigacestat McCann TS: Pathology and bacteriology of adult male Antarctic fur seals, Arctocephalus gazella, dying at Bird Island. South Georgia. Br Vet J 1989, 145:263–275.CrossRef 42. Miranda C, Gamez MI, Navarro JM, Rosa-Fraile M: Endocarditis caused by nonhemolytic group B streptococcus. J Clin Microbiol 1997, 35:1616–1617.PubMed 43. Nickmans S, Verhoye E, Boel A, Van VK, De BH: Possible solution to the problem of nonhemolytic group B streptococcus on Granada medium. J Clin Microbiol 2012, 50:1132–1133.PubMedCrossRef 44. Lopez-Sanchez MJ, Sauvage E, Da CV, Clermont D, Ratsima HE, Gonzalez-Zorn B, et al.: The highly dynamic CRISPR1 system of Streptococcus agalactiae controls the diversity of its mobilome. Mol Microbiol 2012, 85:1057–1071.PubMedCrossRef 45. Verner-Jeffreys DW, Baker-Austin C, Pond MJ, Rimmer GS, Kerr R, Stone D, et al.: Zoonotic disease pathogens in fish used for pedicure. Emerg Infect Dis 2012, 18:1006–1008.PubMedCrossRef Competing interests The authors declare that they have no competing interests.

N Engl J Med 2009, 361:123–134.PubMedCrossRef 40. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al.: Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010, 28:2512–2519.PubMedCrossRef 41. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept

trial. Lancet 2010, 376:245–251.PubMedCrossRef 42. https://www.selleckchem.com/products/tideglusib.html Gelmon KA, Hirte HW, Robidoux A, Tonkin KS, Tischkowitz M, Swenerton K, et al.: Olaparib in patients find more with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011, 12:852–861.PubMedCrossRef 43. Piccart MJ, Floquet A, Scarfone G, Willemse PH, Emerich J, Vergote I, et al.: Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 2003,13(Suppl 2):196–203.PubMedCrossRef 44. Pecorelli

S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, et al.: Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol 2009, selleck 27:4642–4648.PubMedCrossRef 45. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al.: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484–96.PubMedCrossRef Competing interests The authors declare that they have

FER no competing interests. Authors’ contributions Conception and design: RS. Acquisition of data: RS, AG, MAC, FR, EL, CC, PV, JME. Statistical analysis: RS. Manuscript writing: RS, AG, FB, JME. Final approval: all authors.”
“Introduction Childhood cancer survivors exposed to anthracyclines are at increased risk for premature cardiac morbidity and mortality [1–8]. For 30 years after cancer treatment, survivors are 15 times more likely to experience heart failure than the general population [8]. Cardiac effects of the therapy for acute leukemia in childhood are of particular concern. In more than half of the exposed survivors, cardiotoxic treatment was found to be associated with left ventricular (LV) subclinical structural and functional abnormalities, which can progress to clinically manifested heart failure [9]. Diagnosis of cardiac dysfunction and heart failure after anticancer therapy is based on medical history, physical examination and is further confirmed by other tests, mainly echocardiography.

This novel regulatory circuitry between HIF-1α, HIPK2 and p53 molecules gives a mechanistic explanation of the p53 apoptotic inhibition in response

to drug under hypoxia in those tumors that retain a nonfunctional wild-type p53 [58]. Interestingly, HIF-1α may be targeted by zinc ions that induce HIF-1α proteasomal degradation [59], opening a way to reactivate the hypoxia-inhibited HIPK2/p53 pathway that could be exploited in vivo. This finding was Selleckchem eFT-508 corroborated by cDNA microarray studies in hypoxia-treated cancer cells, showing that zinc ions indeed reverse the hypoxia-induced gene transcription [60]. In summary, several different mechanisms that inhibit HIPK2 in tumors were identified, leading selleck inhibitor mainly to impairment of p53 response to drugs but also to induction of oncogenic pathways important in tumor progression, learn more angiogenesis and chemoresistance such as Wnt/β-catenin and HIF-1 (Figure 2). During hypoxia, HIPK2 can be reactivated by zinc treatment that becomes a valuable tool to be used in combination with anticancer drugs to restore the HIPK2/p53 pathway. Figure 2 Schematic representation of HIPK2 activation/inactivation. HIPK2 can be activated by: drugs, IR, UV, roscovitin. The so far known mechanisms of HIPK2 inhibition are: cytoplasmic localization, hypoxia, gene mutation, LOH, and HPV23 E6 or

HMGA1 overexpression. HIPK2 inhibits the oncogenic Wnt/β-catenin and HIF-1 pathways. HIPK2 activates p53 for apoptotic function and inhibits the antiapoptotic CtBP, MDM2 and ΔNp63α proteins. A novel role of HIPK2 in controlling cytokinesis Methane monooxygenase and preventing tetraploidization Recently,

an unexpected subcellular localization and biological function of HIPK2 in cytokinesis was identified [61]. In cytokinesis daughter cells separate by constriction of the cytoplasmic intercellular bridge between the two re-forming nuclei at the final step of cell division. Failure of cytokinesis may generate tetraploid cells. With the exception of rare cell types, such as hepatocytes, which can exist as stable tetraploids, tetraploid cells have chromosome unstable state that can lead to aneuploidy and ultimately to tumorigenic transformation [62]. Alike several abscission’s regulatory and effector components, HIPK2 and its novel target, the histone H2B, was shown to localize within the intercellular bridge at the midbody during cytokinesis. HIPK2 binds directly histone H2B and phosphorylates it at serine residue 14 (Ser14). Despite the apoptotic functions of both HIPK2 and the S14 phosphorylated form of H2B (H2B-S14P), the two proteins co-localize at the midbody (Figure 3), independently of the presence of chromatin in the cleavage plane, DNA damage, and/or apoptosis.